Due to Xmas holidays, our last days of shipping will be as follow: International Dec 18, 2020. USA: Dec 21, 2020. The shipments will resume as usual on International: Jan 8, 2021 and USA: Jan 4, 2021.
CDK1/CyclinB1, Active(C22-10G)

CDK1/CyclinB1, Active(C22-10G)

  • $226.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant full-length human CDK1 and CyclinB1 were co-expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag on both proteins.

Species :Human

Tag :GST tag

Expression System:Sf9 insect cells using baculovirus

Sequence :Full Length

Genbank Number :NM_001786

Genbank Number 2 :NM_031966

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Kinase Assay, Western Blot

Molecular Weight :~58 kDa and CyclinB1 ~75 kDa

Gene Aliases :CDK1: CDC2 CyclinB1: CCNB1, CCNB

Scientific Background :CDK1 or Cell Division Control protein 1 is essential for the completion of START, the controlling event in the cell cycle that is required to initiate mitosis. CDK1 is a catalytic subunit of a protein kinase complex, called the M-Phase Promoting Factor that induces entry into mitosis and is universal among eukaryotes (1). Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. Therapeutic potential of CDK inhibitor NU2268 in androgen-independent prostate cancer has also been demonstrated (2).

References :
1. Vantieghem, A. et al: Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J. Biol. Chem. 2002; 277(40):37718-31.

2. Rigas, A.C. et al: Therapeutic potential of CDK inhibitor NU2268 in androgen-independent prostate cancer. Oncogene. 2007; 18.

Product Sheets (By Lot #) :

F625-2.pdf

W3125-8.pdf

Research Areas :Cancer, Cell Cycle, Ser/Thr Kinases, Cancer, Cell Cycle, Ser/Thr Kinases